NAD+ IV therapy is a cornerstone of modern longevity medicine. The clinical evidence for its effects on cellular repair, mitochondrial function, and neurological health continues to grow. Patients seek it out specifically. They are willing to pay premium prices for it. They walk in ready to commit to a full protocol.
And then a significant number of them quit before session 4.
The pattern is so consistent across longevity clinics that it has become an accepted cost of doing business. But it should not be. NAD+ patient attrition is not random. It follows a predictable timeline with predictable triggers. And every single trigger has a specific, implementable countermeasure.
This guide is a session-by-session breakdown of where NAD+ patients disengage, why, and exactly what to do about it.
The NAD+ Drop-Off Timeline
Before diving into solutions, here is the reality of NAD+ patient retention mapped across a standard 6-session initial protocol.
The critical window is sessions 2 through 4. This 3-week period is where the majority of NAD+ patients are lost. Everything in this guide is designed to get patients through that window.
Why NAD+ Has Uniquely High Drop-Off
NAD+ IV therapy has characteristics that make it more drop-off prone than other longevity protocols.
1. Immediate, uncomfortable side effects. NAD+ infusions commonly cause flushing, nausea, chest tightness, headaches, and fatigue during and after the infusion. These are well-documented, dose-dependent, and temporary. But for the patient experiencing them for the first time at home on a Tuesday night, they are alarming.
2. Long infusion times create schedule friction. A standard NAD+ IV infusion takes 2 to 4 hours. Patients must block half a day from their schedule every week for 6 weeks. One scheduling conflict becomes a missed session. One missed session becomes two. Two becomes permanent.
3. Benefits are delayed. Unlike some interventions where patients feel an immediate difference, NAD+ benefits accumulate over weeks. The patient is enduring side effects now and being promised benefits later. That is a difficult psychological equation.
4. High cost per session. NAD+ IV therapy is premium-priced, typically $250 to $1,000 per infusion. A 6-session protocol represents a $1,500 to $6,000 commitment. Every side effect, every scheduling inconvenience, every moment of doubt is weighed against that number.
5. The at-home recovery component is unsupported. The infusion happens in-clinic with professional supervision. The recovery happens at home with no supervision. The 24 to 72 hours post-infusion is when side effects peak. That is exactly when the patient is alone with their concerns.
Session-by-Session Retention Playbook
Here is what to do before, during, and after each session to maximize retention through the full protocol.
Pre-Protocol: Before Session 1
The retention battle starts before the first infusion. How you set expectations in the initial consultation directly predicts whether the patient will make it to session 4.
Set realistic expectations. Do not oversell the experience. Specifically address: "You will likely experience some side effects during and after the first 2 to 3 infusions. These are normal, expected, and temporary. Here is exactly what to expect." Patients who are warned about side effects in advance are significantly less likely to interpret them as something going wrong.
Map the full protocol timeline. Show the patient a visual timeline of all 6 sessions with their scheduled dates. Seeing the end point makes the commitment feel finite and manageable rather than open-ended.
Address the cost upfront. If you offer package pricing, present it now. A patient who has prepaid for 6 sessions has a financial incentive to complete the protocol that a per-session payer does not.
Automated action: Send a pre-treatment information packet 48 hours before Session 1. Include: what to eat and avoid before the infusion, what to wear, how long it takes, what side effects to expect, and hydration instructions. This reduces anxiety and demonstrates clinical thoroughness.
Session 1: The Honeymoon
The patient is excited. This is the easy session from a retention perspective. The goal here is not to sell the patient on NAD+ (they are already sold) but to build the communication patterns that will sustain them through weeks 2 to 4.
During the infusion: Explain what is happening in real time. "You might start feeling flushing in your chest and face. That is the NAD+ activating your sirtuins. It is temporary and completely normal." Narrating the experience reduces anxiety and builds trust.
Before they leave: Confirm their Session 2 date. Ask for their preferred communication channel (SMS or email). Tell them they will hear from you tomorrow.
Automated action (24 hours post-infusion): Send a symptom check-in. "How are you feeling after your first NAD+ session? Any headache, nausea, or fatigue? These are common and usually resolve within 24 to 48 hours." This is the most important automated message in the entire protocol. It establishes that the clinic monitors patients between visits and creates a communication channel the patient will rely on during harder sessions.
Automated action (48 hours post-infusion): Follow-up if the patient reported symptoms. "Checking back in. How are the symptoms today? Most patients find them significantly reduced by day 2 to 3." If the patient did not respond to the 24-hour check-in, send a gentle nudge. Non-response at session 1 is a leading indicator of drop-off by session 3.
Session 2: The Reality Check
This is where retention gets difficult. The novelty has worn off. Side effects from session 1 are fresh in memory. The patient is deciding whether to continue based on how they felt after the first infusion, not on the clinical evidence for the protocol.
Pre-session message (day before): "Your second NAD+ session is tomorrow. Many patients find that side effects are milder on the second infusion as your body adapts. Remember to hydrate well today. See you at [time]." This is preemptive anxiety management. The patient is almost certainly wondering whether the side effects will be as bad. Tell them they probably will not be.
During the infusion: Ask about their experience since session 1. Listen. Validate. If they mention side effects, normalize them and explain the physiological mechanism. "The headache is your body upregulating NAD+ dependent repair pathways. It means the therapy is doing what it should."
Automated action (24 hours post): Same symptom check-in. But add a forward-looking element. "After session 2, most patients start to notice the side effects diminishing. Sessions 3 and 4 are typically much more comfortable. You are past the hardest part."
Automated action (72 hours post): If the patient reported significant side effects after either session, send a message attributed to the provider. "Dr. [Name] reviewed your session notes and wanted you to know that your response is within the expected range. If you have any questions before session 3, reply here." Provider-attributed communication carries significantly more weight than system messages.
Session 3: The Make-or-Break Session
If you get a patient to session 3, you have a 70 to 80% chance of getting them to session 6. If you lose them before session 3, they are almost certainly gone permanently. This is the highest-leverage retention point in the entire protocol.
Pre-session message (2 days before): "Your third NAD+ session is on [day]. You are halfway through the initial protocol. Patients typically report that sessions 3 and 4 are when the shift happens. The side effects continue to decrease and the benefits start to emerge. We are looking forward to seeing you."
Critical intervention for no-shows: If a patient misses session 3 without rescheduling, trigger an immediate human follow-up within 24 hours. Not an automated message. A phone call from the care coordinator or the provider. This is the single most important retention intervention in NAD+ therapy. The cost of a 5-minute phone call is trivial compared to the $1,500 to $4,000 in remaining protocol revenue at stake.
Automated action (24 hours post): Symptom check-in with biomarker framing. "How are you feeling after session 3? By this point, your NAD+ levels are significantly elevated compared to baseline. The cellular repair processes we discussed are actively underway. Many patients start noticing improved energy and mental clarity in the coming week."
Session 4: The Turning Point
The patient has made it through the hardest part. Side effects are typically manageable or gone. Benefits are starting to emerge. The psychological equation has shifted from "am I sure about this?" to "this is working."
During the infusion: Celebrate the milestone. "You are past the halfway point. How are you feeling compared to session 1?" Let the patient articulate their own progress. When patients verbalize their improvement, it reinforces their commitment more effectively than when the provider tells them they are improving.
Automated action (24 hours post): Lighter tone. "Session 4 done. Most patients find that from here on, each session gets easier and the benefits get more noticeable. Two more to go."
Mid-protocol labs: If your protocol includes mid-cycle blood work, schedule it between sessions 4 and 5. Having objective biomarker data to share at session 5 is a powerful retention tool for the maintenance transition that comes after session 6.
Sessions 5 and 6: Completion and the Maintenance Cliff
The patient is going to finish the protocol. The retention challenge shifts from "will they complete the initial cycle?" to "will they transition to maintenance?"
This is the second critical drop-off point. The patient feels better. They achieved what they came for. They see no reason to continue paying for monthly infusions to maintain something that already feels resolved.
Session 5 automated action: Begin seeding the maintenance conversation. "One session left after this one. After your initial protocol, most patients transition to monthly maintenance infusions to sustain their NAD+ levels. We will discuss your specific maintenance plan at session 6."
Session 6 (in-clinic): This is a consultation, not just an infusion. Review their progress. Show biomarker improvements if mid-cycle labs were done. Present the maintenance plan with specific scheduling. Frame maintenance as protecting the investment they already made. "You have spent 6 weeks rebuilding your NAD+ levels. Without maintenance, those levels decline back to baseline within 2 to 3 months. Monthly infusions sustain what you have built."
Automated action (1 week post-completion): "Congratulations on completing your NAD+ protocol. Your maintenance infusion is scheduled for [date, 4 weeks out]. Between now and then, continue your hydration and supplement protocol to maximize the benefits of your initial cycle."
Automated action (3 weeks post-completion, 1 week before maintenance): "Your first maintenance NAD+ infusion is next [day]. This session is shorter (60 to 90 minutes vs 2 to 4 hours) and side effects are typically minimal at maintenance dosing. See you then."
The Between-Session Communication Framework
Pulling all of the above together, here is the complete between-session messaging timeline for a standard 6-session NAD+ protocol.
This is 14 to 16 automated touchpoints across 7 to 8 weeks, plus one human phone call for missed Session 3. For a clinic with 50 concurrent NAD+ patients, that is 700 to 800 messages per protocol cycle. Impossible to execute manually. Straightforward to automate.
The Side Effect Communication Guide
Side effect anxiety is the number one driver of NAD+ drop-off. Here is a reference guide for the most common side effects and the messaging that addresses each one.
Important: This guide covers expected side effects. Any automated system should include clear escalation language: "If you are experiencing severe symptoms, difficulty breathing, or anything that feels like an emergency, please call [clinic number] or 911 immediately." AI should never triage genuine emergencies.
Biomarker Tracking for NAD+ Retention
Objective data is the strongest retention tool available. When a patient can see that their biomarkers are improving, subjective day-to-day fluctuations lose their power to drive disengagement.
Key biomarkers to track across an NAD+ protocol:
1. Intracellular NAD+ levels — Direct measurement of what the therapy is designed to increase. Show the patient their baseline versus mid-protocol versus completion levels.
2. Inflammatory markers (hs-CRP, IL-6) — NAD+ has anti-inflammatory effects. Tracking these gives patients objective evidence that the protocol is reducing systemic inflammation.
3. Cellular energy markers (ATP production, mitochondrial function) — If your lab panel includes these, they directly demonstrate the mechanism of action that patients are paying for.
4. Cognitive function assessments — Standardized cognitive testing at baseline and completion can quantify the neurological benefits patients often report subjectively.
5. Biological age markers (epigenetic clocks, telomere length) — For patients on comprehensive longevity programs, showing biological age improvement across the NAD+ protocol is the most compelling retention data point available.
How to use this for retention: At session 5 or 6, present the biomarker comparison. "Your NAD+ levels have increased by X%. Your inflammatory markers are down Y%. Your biological age assessment shows Z improvement." Then tie it to maintenance: "Monthly infusions are designed to sustain these levels. Without maintenance, they are projected to decline back to baseline within 2 to 3 months."
The Maintenance Retention Strategy
Getting patients through the initial 6-session protocol is only half the battle. The second half is transitioning them to ongoing monthly maintenance where the real lifetime value accumulates.
A patient who completes 6 sessions and stops is worth $1,500 to $6,000. A patient who transitions to maintenance and stays for 2 years is worth $10,000 to $30,000.
1. Start the maintenance conversation at session 5, not session 6. If the first time a patient hears about maintenance is at the final session, it feels like an upsell. If they hear about it at session 5, it feels like the natural next step.
2. Present maintenance as protecting the investment. "You have invested 6 weeks and $X in rebuilding your NAD+ levels. Maintenance is how you protect that investment." This is not a sales tactic. It is clinically accurate.
3. Schedule the first maintenance session before the patient leaves session 6. Do not let them go home to "think about it." The decision is easier in the moment of completion when they feel the results and the momentum is highest.
4. Automate quarterly biomarker check-ins. Even during maintenance, patients need objective evidence that the protocol is still delivering value. Quarterly labs with progress updates sustain engagement indefinitely.
5. Offer a maintenance package. Annual maintenance pricing (prepaid 12 monthly sessions at a discount) creates financial commitment and eliminates the monthly re-decision point.
Scaling This Across Your Practice
This playbook is specific to NAD+ but the framework applies to any longevity protocol: HRT, peptide therapy, senolytics, or any other multi-session, multi-week treatment.
The principles are consistent:
- •Pre-treatment expectation setting reduces anxiety
- •Post-treatment symptom check-ins prevent fear-driven drop-off
- •Provider-attributed communication builds trust during the hardest sessions
- •Biomarker progress updates sustain motivation when subjective improvements are slow
- •Maintenance transition planning starts before protocol completion, not after
- •Human intervention at critical drop-off points (missed session 3 for NAD+) is worth the time investment
For a clinic managing 50 to 200 concurrent NAD+ patients, the automated communication volume ranges from 700 to 3,200 messages per protocol cycle. Add HRT, peptides, and supplements, and the total easily exceeds 5,000 to 10,000 protocol-aware messages per month.
A2V2 Medical Agents are designed to handle exactly this. Protocol-stage messaging, symptom-specific check-ins, biomarker progress updates, inactivity detection, and maintenance transition sequences, all running through HIPAA-compliant infrastructure with complete audit trails.
See how Medical Agents automate clinical follow-ups · Why 73% of longevity patients quit · Calculate your revenue at risk from patient drop-off
Try the ROI calculator · AI for longevity clinics
The Bottom Line
NAD+ patient attrition is not a mystery. It follows a predictable timeline. Sessions 2 through 4 are the danger zone. Side effects are the primary trigger. Lack of between-session communication is the root cause.
Every touchpoint in this playbook addresses a specific, documented drop-off trigger at the specific moment it occurs. The side effect communication guide gives patients the reassurance they need when they need it. The biomarker tracking gives them the objective proof that sustains motivation through the delayed-benefit window. The maintenance transition strategy protects the lifetime value of every patient who makes it through the initial protocol.
The clinics that implement this, whether manually for a small patient base or through AI automation at scale, will retain significantly more NAD+ patients, recover significantly more revenue, and build a patient base that stays engaged for years rather than weeks.
